Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lia Gore

Showing results (31-40 of 119) with videos related to

Pageof 12
Sort By:
Pediatric Blood & Cancer|July 25, 2023
Children's Oncology Group blueprint for research: Acute lymphoblastic leukemiaElizabeth A Raetz, Deepa Bhojwani, Meenakshi Devidas, et al.
Pediatric Blood & Cancer|June 26, 2014
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumorsRobin E Norris, Suzanne Shusterman, Lia Gore, et al.
Cancer Chemotherapy and Pharmacology|December 7, 2007
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumorsLaura Q M Chow, S Gail Eckhardt, Cindy L O'Bryant, et al.
Pediatric Blood & Cancer|August 14, 2012
Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemiasAbeer Abd Elmoneim, Lia Gore, Rebecca M Ricklis, et al.
Investigational New Drugs|November 18, 2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumorsAlbiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, et al.
Transplantation and Cellular Therapy|September 9, 2023
INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic LeukemiaAdam J Lamble, Amy Moskop, Michael A Pulsipher, et al.
Investigational New Drugs|July 12, 2008
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapyChristopher Lieu, Laura Chow, A Scott Pierson, et al.
Pediatric Blood & Cancer|July 10, 2021
A prospective survey study of lower urinary tract dysfunction in childhood cancer survivors after vincristine and/or doxorubicin chemotherapySarah L Hecht, Alan Quach, Dexiang Gao, et al.
Cancer|February 25, 2023
Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaManon Queudeville, Anthony S Stein, Franco Locatelli, et al.
Leukemia & Lymphoma|August 1, 2023
Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a reviewFranco Locatelli, Bijal Shah, Tracy Thomas, et al.
Pageof 12

Showing results (31-40 of 119) with videos related to

Sort By:
Pageof 12
Pediatric Blood & Cancer|July 25, 2023
Children's Oncology Group blueprint for research: Acute lymphoblastic leukemiaElizabeth A Raetz, Deepa Bhojwani, Meenakshi Devidas, et al.
Pediatric Blood & Cancer|June 26, 2014
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumorsRobin E Norris, Suzanne Shusterman, Lia Gore, et al.
Cancer Chemotherapy and Pharmacology|December 7, 2007
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumorsLaura Q M Chow, S Gail Eckhardt, Cindy L O'Bryant, et al.
Pediatric Blood & Cancer|August 14, 2012
Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemiasAbeer Abd Elmoneim, Lia Gore, Rebecca M Ricklis, et al.
Investigational New Drugs|November 18, 2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumorsAlbiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, et al.
Transplantation and Cellular Therapy|September 9, 2023
INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic LeukemiaAdam J Lamble, Amy Moskop, Michael A Pulsipher, et al.
Investigational New Drugs|July 12, 2008
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapyChristopher Lieu, Laura Chow, A Scott Pierson, et al.
Pediatric Blood & Cancer|July 10, 2021
A prospective survey study of lower urinary tract dysfunction in childhood cancer survivors after vincristine and/or doxorubicin chemotherapySarah L Hecht, Alan Quach, Dexiang Gao, et al.
Cancer|February 25, 2023
Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaManon Queudeville, Anthony S Stein, Franco Locatelli, et al.
Leukemia & Lymphoma|August 1, 2023
Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a reviewFranco Locatelli, Bijal Shah, Tracy Thomas, et al.
Pageof 12